FDA Approves Takeda and Protagonist Blood Cancer Drug
The US FDA has approved rusfertide, a new drug developed by Takeda Pharmaceutical and Protagonist Therapeutics to treat polycythemia vera. The treatment offers a less-invasive option for thousands of patients who previously relied on frequent bloodletting.
Xurve View
Insights:
Xurve View